文献速递冠心病

新冠疫情期间急性STEMI溶栓治疗疗效与安全性分析

[Analysis on the efficacy and safety of fibrinolytic therapy in patients with acute ST-segment elevation myocardial infarction during the COVID-19 epidemic].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2020-01-01

该研究回顾性分析2020年2月29日至4月3日在武汉协和医院接受溶栓治疗的7例急性STEMI患者,评估溶栓疗效与安全性,并通过优化溶栓流程(专职小组、三级防护、就地隔离溶栓)缩短首次心电图至溶栓时间。结果显示6例再通、无出血、无死亡,优化后时间由201/106分钟降至42-54分钟。

要点

  • 疫情期间急性STEMI溶栓安全有效,7例中6例再通、无出血、无死亡。
  • 优化溶栓流程后首次心电图至溶栓时间由201/106分钟缩短至42-54分钟。
  • 建议有溶栓适应证的急性STEMI在疫情防控前提下首选溶栓并优化流程。

核心结论

  • 新冠疫情期间急性STEMI患者溶栓安全有效、简便易行,建议有适应证者首选溶栓。
  • 在兼顾疫情防控与医务人员防护前提下优化溶栓流程可缩短心肌缺血时间。

研究设计与样本

  • 回顾性分析2020年2月29日至4月3日华中科技大学同济医学院附属协和医院本部7例急性STEMI并行溶栓治疗的患者。
  • 优化措施包括成立专职溶栓小组、三级防护、定人定岗定位、就地隔离溶栓、开放绿色通道。
  • 溶栓前送检血常规、2019-nCoV抗体及核酸检测,溶栓后完善肺部CT。
  • 通过比较流程改进前后首次心电图至溶栓时间评估优化效果。

主要发现

  • 7例溶栓患者中6例再通,无出血并发症。
  • 溶栓后5例住院,平均住院天数19.6 d。
  • 随访至2020年4月14日,7例患者无1例死亡。
  • 优化前首次心电图至溶栓时间分别为201、106 min。
  • 优化后后5例首次心电图至溶栓时间分别为42、46、51、43、54 min,明显缩短。

临床怎么用

  • 疫情期间对具有溶栓适应证的急性STEMI可首选溶栓治疗。
  • 在确保疫情防控与医务人员防护前提下,通过专职小组和隔离流程优化缩短首次心电图至溶栓时间。

局限性

  • 回顾性分析,样本量仅7例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of fibrinolysis strategy in patients with acute ST-segment elevation myocardial infarction (STEMI) during the COVID-19 epidemic, and to provide reference value for optimization of fibrinolytic process on the premise of prevention and control of COVID-19 transmission, including self-protection of medical staff. Methods: The efficacy and safety of fibrinolysis were retrospectively analyzed in 7 patients with acute STEM, who hospitalized from February 29, 2020 to April 3, 2020 in the Department of Cardiology, Wuhan Union Hospital of Tongji Medical College, Huazhong University of Science and Technology. To optimize the fibrinolytic process on the premise of prevention and control of COVID-19 transmission, including self-protection of medical staff, a full-time medical team in charge of fibrinolysis under third-grade protection was established. The acute STEMI patients were treated immediately in a fixed and isolated area in emergency department before receiving green channel fibrinolysis. Blood samples for complete blood count, COVID-19 antibody test and nasopharyngeal swab samples for COVID-19 nucleic acid test were made before fibrinolysis, while the chest CT examination was accomplished after fibrinolysis. By comparing differences of time from the first electrocardiogram (ECG) to fibrinolysis before and after the improvement of fibrinolytic process, the effect of optimization of the fibrinolytic process was evaluated. Results: In the present study, seven patients with acute STEMI received fibrinolysis therapy, 6 of them achieved reperfusion and no bleeding was observed in all of the patients. Five out of the 7 patients were hospitalized after fibrinolysis, and the hospitalization days were 19.6 days on average. By following up to April 14, 2020, none of the 7 patients died. The first 2 patients were treated according to the routine medical procedure and the time from the first ECG to fibrinolysis were 201 and 106 minutes, respectively. After the optimization of the fibrinolytic process, the time from the first ECG to fibrinolysis of the last 5 patients were 42, 46, 51, 43 and 54 minutes, respectively,which was significantly shorter than that before optimization. Conclusions: During the COVID-19 epidemic, fibrinolysis in patients with acute STEMI is safe, effective and easy to implement. Therefore, it is recommended as the top priority for the patients with acute STEMI with indications for fibrinolysis. On the premise of prevention and control of COVID-19 transmission, including self-protection of medical staff, the duration of myocardial ischemia can be shortened by optimization of the fibrinolytic process. 目的: 评估在新型冠状病毒肺炎疫情防控期间急性ST段抬高型心肌梗死(STEMI)溶栓疗效及风险,在兼顾疫情防控、确保防护的条件下为急性STEMI溶栓治疗最优化提供参考。 方法: 回顾性分析2020年2月29日至4月3日在华中科技大学同济医学院附属协和医院本部确诊为急性STEMI并行溶栓治疗的7例患者,评估其溶栓疗效及风险;在保障疫情防控、确保防护的前提下优化溶栓流程,成立专职溶栓小组,启动三级防护,定人、定岗、定位,就地隔离溶栓,开放溶栓绿色通道,溶栓前送检血常规、新型冠状病毒肺炎(2019-nCoV)抗体检测、2019-nCoV核酸检测,待溶栓治疗结束后完善肺部CT;通过流程改进前后首次心电图至溶栓时间的比较来评估流程优化效果。 结果: 急性STEMI并行溶栓治疗患者共7例,6例再通,无出血并发症。溶栓后7例患者中有5例住院,平均住院天数19.6 d。随访至2020年4月14日,7例患者无1例死亡。最初的2例患者按常规医疗流程诊治,后5例患者按照优化后流程进行诊治。首次心电图至溶栓时间优化前分别为201、106 min,优化后分别为42、46、51、43、54 min,时间明显缩短。 结论: 在新型冠状病毒肺炎疫情防控期间,急性STEMI患者溶栓安全有效、简便、易行。对于具有溶栓适应证的急性STEMI建议首选溶栓治疗,在兼顾疫情防控、确保防护的前提下,优化溶栓流程可以缩短总心肌缺血时间。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wei F, Shuai XX, Chen ZJ, et al. [Analysis on the efficacy and safety of fibrinolytic therapy in patients with acute ST-segment elevation myocardial infarction during the COVID-19 epidemic]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020. PMID: 32842256. doi:10.3760/cma.j.cn112148-20200331-00268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。